Savara Inc. (NASDAQ:SVRA – Free Report) – HC Wainwright decreased their Q3 2026 earnings per share estimates for shares of Savara in a report released on Wednesday, August 12th. HC Wainwright analyst A. Fein now forecasts that the company will earn ($0.16) per share for the quarter, down from their previous estimate of ($0.15). The consensus estimate for Savara’s current full-year earnings is ($0.57) per share. HC Wainwright also issued estimates for Savara’s Q4 2026 earnings at ($0.15) EPS, FY2026 earnings at ($0.62) EPS, FY2027 earnings at ($0.37) EPS and FY2028 earnings at ($0.06) EPS.
SVRA has been the subject of a number of other reports. Weiss Ratings reissued a “sell (d-)” rating on shares of Savara in a research note on Friday, July 17th. Oppenheimer started coverage on Savara in a research note on Friday, April 24th. They issued an “outperform” rating and a $11.00 price target for the company. Finally, Wall Street Zen raised Savara from a “sell” rating to a “hold” rating in a research report on Saturday, June 13th. One analyst has rated the stock with a Strong Buy rating, six have given a Buy rating and one has assigned a Sell rating to the company. According to data from MarketBeat, Savara has an average rating of “Moderate Buy” and an average price target of $10.14.
Savara Stock Down 7.5%
Shares of NASDAQ SVRA opened at $5.27 on Friday. The company has a quick ratio of 13.47, a current ratio of 13.47 and a debt-to-equity ratio of 0.17. The company has a market cap of $1.08 billion, a price-to-earnings ratio of -9.09 and a beta of 0.29. Savara has a 12-month low of $2.68 and a 12-month high of $7.01. The firm’s 50-day simple moving average is $5.65 and its 200 day simple moving average is $5.48.
Savara (NASDAQ:SVRA – Get Free Report) last posted its quarterly earnings data on Tuesday, August 11th. The company reported ($0.16) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.14) by ($0.02).
Institutional Trading of Savara
Large investors have recently bought and sold shares of the business. Swedbank AB boosted its holdings in shares of Savara by 54.5% in the 4th quarter. Swedbank AB now owns 850,000 shares of the company’s stock worth $5,126,000 after purchasing an additional 300,000 shares in the last quarter. Renaissance Technologies LLC raised its holdings in Savara by 96.5% during the 1st quarter. Renaissance Technologies LLC now owns 652,672 shares of the company’s stock valued at $3,564,000 after buying an additional 320,572 shares during the last quarter. F m Investments LLC grew its stake in shares of Savara by 56.5% in the fourth quarter. F m Investments LLC now owns 678,813 shares of the company’s stock worth $4,093,000 after purchasing an additional 245,100 shares during the last quarter. Nan Fung Trinity HK Ltd. bought a new position in shares of Savara during the fourth quarter valued at approximately $10,182,000. Finally, Orbimed Advisors LLC bought a new position in Savara in the first quarter worth about $3,467,000. 87.93% of the stock is currently owned by institutional investors and hedge funds.
About Savara
Savara Inc (NASDAQ:SVRA) is a clinical-stage biopharmaceutical company focused on developing and commercializing therapies for rare respiratory diseases. The company specializes in in-licensing, advancing and potentially bringing to market novel treatments that address severe pulmonary conditions with high unmet medical need.
The company’s lead candidate, Molgradex (recombinant human granulocyte-macrophage colony-stimulating factor, or GM-CSF), is under regulatory review for the treatment of autoimmune pulmonary alveolar proteinosis (PAP), a rare lung disease characterized by the accumulation of surfactant.
See Also
- Five stocks we like better than Savara
- Inside Teledyne’s Bold Bet on the Future of Medical Imaging
- Why Are Analysts Freaking Out About Apple’s All-Glass iPhone?
- Asian Market Circuit Breakers Hit Stocks, Not AI Demand
- Riot Platforms Re-Wires the Ledger for a $9B AI Power Play
Receive News & Ratings for Savara Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Savara and related companies with MarketBeat.com's FREE daily email newsletter.
